CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Inclusion criteria

• ✓. Subjects diagnosed with relapsed/refractory lymphoma/leukemia:
• ✓. Relapsed/refractory T-cell malignant lymphoma: patients who have not remission and recurrence after at least 2 courses of standardized second-line or above treatment (including hematopoietic stem cell transplantation).
• ✓. Relapsed/refractory T-cell acute lymphocytic or myeloid leukemia meeting any of the following criteria:
• ✓. Bone marrow flow cytometry detected tumor cells as CD7 and/or extramedullary lesions with a clear diagnosis of CD7 by pathological immunohistochemistry at the time of enrollment screening;
• ✓. If tumor cells are detected in peripheral blood during enrollment screening, flow cytometry must be used to detect that the immunophenotype of tumor cells on the surface of tumor cells is both negative for CD4 and CD8. If the immunophenotype on the surface of peripheral blood tumor cells is not CD4 and CD8 negative, the proportion of peripheral blood tumor cells must be ≤1%;
• ✓. Expected survival greater than 3 months from the date of signing the informed consent form;
• ✓. Subjects with a performance status of 0\~2 in the Eastern Cooperative Oncology Group (ECOG) score;
• ✓. 14 years old≤ age ≤ 75 years old, male or female;